Reactions 562 - 5 Aug 1995

■ Clomifene should not normally be used for > 6cycles, recommends the Committee on Safety ofMedicines (CSM) and the Medicines Control Agency(MCA). Recent evidence indicates that > 12 cycles ofclomifene may increase the risk of ovarian cancer.However, there is no evidence to suggest that therecommended treatment duration for clomifene (3–6months) is associated with an increased risk of ovariancancer, according to a report by the CSM and MCA inthe July issue of Current Problems inPharmacovigilance.Clomiphene (Clomid, Serophene): possible association with ovarian cancer:risk may be increased in patients treated for longer than recommended. CurrentProblems in Pharmacovigilance 21: 7, Jul 1995 800377643

1

Reactions 5 Aug 1995 No. 5620114-9954/10/0562-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved